$ABVC
ABVC BIOPHARMA, INC.

2024 Q4 Form 10-Q Financial Statement

#000121390024097840 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $389.3K
YoY Change 2350.74%
Cost Of Revenue $296.00
YoY Change -99.0%
Gross Profit $389.0K
YoY Change -2933.07%
Gross Profit Margin 99.92%
Selling, General & Admin $301.2K
YoY Change -74.52%
% of Gross Profit 77.44%
Research & Development $37.83K
YoY Change -73.23%
% of Gross Profit 9.72%
Depreciation & Amortization $7.013K
YoY Change -5.98%
% of Gross Profit 1.8%
Operating Expenses $339.0K
YoY Change -84.17%
Operating Profit $49.95K
YoY Change -102.32%
Interest Expense -$212.7K
YoY Change -117.46%
% of Operating Profit -425.89%
Other Income/Expense, Net -$183.9K
YoY Change -84.86%
Pretax Income -$133.9K
YoY Change -96.03%
Income Tax $355.00
% Of Pretax Income
Net Earnings -$186.6K
YoY Change -94.38%
Net Earnings / Revenue -47.93%
Basic Earnings Per Share -$0.02
Diluted Earnings Per Share -$0.02
COMMON SHARES
Basic Shares Outstanding 12.98M shares 12.42M shares
Diluted Shares Outstanding 12.41M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $208.2K
YoY Change -63.39%
Cash & Equivalents $137.3K
Short-Term Investments $70.81K
Other Short-Term Assets $723.8K
YoY Change -5.26%
Inventory
Prepaid Expenses
Receivables $1.529K
Other Receivables $1.204M
Total Short-Term Assets $2.148M
YoY Change -13.84%
LONG-TERM ASSETS
Property, Plant & Equipment $7.931M
YoY Change -0.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $146.9K
YoY Change -94.51%
Other Assets $1.417M
YoY Change -13.39%
Total Long-Term Assets $12.31M
YoY Change -12.65%
TOTAL ASSETS
Total Short-Term Assets $2.148M
Total Long-Term Assets $12.31M
Total Assets $14.46M
YoY Change -12.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $3.546M
YoY Change -0.34%
Deferred Revenue $79.50K
YoY Change 0.0%
Short-Term Debt $866.3K
YoY Change 1.61%
Long-Term Debt Due $952.2K
YoY Change
Total Short-Term Liabilities $6.316M
YoY Change 17.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $167.9K
YoY Change -67.26%
Total Long-Term Liabilities $167.9K
YoY Change -92.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.316M
Total Long-Term Liabilities $167.9K
Total Liabilities $6.484M
YoY Change -13.9%
SHAREHOLDERS EQUITY
Retained Earnings -$70.55M
YoY Change 13.23%
Common Stock $12.71K
YoY Change 163.57%
Preferred Stock
YoY Change
Treasury Stock (at cost) $8.902M
YoY Change -2.17%
Treasury Stock Shares
Shareholders Equity $8.358M
YoY Change
Total Liabilities & Shareholders Equity $14.46M
YoY Change -12.83%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$186.6K
YoY Change -94.38%
Depreciation, Depletion And Amortization $7.013K
YoY Change -5.98%
Cash From Operating Activities $171.7K
YoY Change -112.66%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -145.4K
YoY Change -108.8%
NET CHANGE
Cash From Operating Activities 171.7K
Cash From Investing Activities
Cash From Financing Activities -145.4K
Net Change In Cash 26.33K
YoY Change -88.07%
FREE CASH FLOW
Cash From Operating Activities $171.7K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12711345 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12711345 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7940298 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7940298 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
12712 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
7940 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4055345 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12405261 shares
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40700
dei Entity Registrant Name
EntityRegistrantName
ABVC BioPharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0014658
dei Entity Address Address Line1
EntityAddressAddressLine1
44370 Old Warm Springs Blvd.
dei Entity Address City Or Town
EntityAddressCityOrTown
Fremont
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94538
dei City Area Code
CityAreaCode
(510)
dei Local Phone Number
LocalPhoneNumber
668-0881
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
ABVC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12975492 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
137344 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60155 usd
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
632529 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
656625 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1529 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1530 usd
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
70809 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
79312 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
91291 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
101051 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
2148327 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1656709 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7931478 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7969278 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
507659 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
809283 usd
CY2024Q3 us-gaap Long Term Investments
LongTermInvestments
2333904 usd
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
2527740 usd
CY2024Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
75898 usd
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
78789 usd
CY2024Q3 us-gaap Security Deposit
SecurityDeposit
60916 usd
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
62442 usd
CY2024Q3 abvc Prepayment For Longterm Investments Noncurrent
PrepaymentForLongtermInvestmentsNoncurrent
1280512 usd
CY2023Q4 abvc Prepayment For Longterm Investments Noncurrent
PrepaymentForLongtermInvestmentsNoncurrent
1274842 usd
CY2024Q3 us-gaap Assets
Assets
14462845 usd
CY2023Q4 us-gaap Assets
Assets
14492599 usd
CY2024Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
866250 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
899250 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3632927 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3696380 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
79500 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
79500 usd
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
112946 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
365458 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
401826 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
419270 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
173132 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6315642 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5932490 usd
CY2024Q3 us-gaap Security Deposit Liability
SecurityDepositLiability
25680 usd
CY2023Q4 us-gaap Security Deposit Liability
SecurityDepositLiability
21680 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
142201 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
407457 usd
CY2024Q3 us-gaap Liabilities
Liabilities
6483523 usd
CY2023Q4 us-gaap Liabilities
Liabilities
6361627 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
87308080 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
82636966 usd
CY2023Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
451480 usd
CY2024Q3 abvc Stock Subscription Received In Advance
StockSubscriptionReceivedInAdvance
31040 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70552277 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65420095 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
461282 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
516387 usd
CY2024Q3 us-gaap Treasury Stock Value
TreasuryStockValue
8902371 usd
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
8901668 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
8358466 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8388050 usd
CY2024Q3 us-gaap Minority Interest
MinorityInterest
-379144 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-257078 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7979322 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8130972 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14462845 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14492599 usd
CY2024Q3 us-gaap Revenues
Revenues
389276 usd
CY2023Q3 us-gaap Revenues
Revenues
15884 usd
us-gaap Revenues
Revenues
507623 usd
us-gaap Revenues
Revenues
150265 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
296 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
29614 usd
us-gaap Cost Of Revenue
CostOfRevenue
763 usd
us-gaap Cost Of Revenue
CostOfRevenue
162831 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
388980 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
-13730 usd
us-gaap Gross Profit
GrossProfit
506860 usd
us-gaap Gross Profit
GrossProfit
-12566 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
301208 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1182093 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1772916 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3841633 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37825 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
141310 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
147292 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
990731 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
817740 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2957736 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1409969 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
339033 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2141143 usd
us-gaap Operating Expenses
OperatingExpenses
4877944 usd
us-gaap Operating Expenses
OperatingExpenses
6242333 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
49947 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2154873 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4371084 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6254899 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
44261 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
40246 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
75451 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
147998 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
219533 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1218624 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1164248 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1390039 usd
CY2024Q3 abvc Operating Sublease Income
OperatingSubleaseIncome
12000 usd
abvc Operating Sublease Income
OperatingSubleaseIncome
36478 usd
abvc Operating Sublease Income
OperatingSubleaseIncome
53900 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
30429 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-25059 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
26284 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-55625 usd
CY2024Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-67885 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-146942 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16864 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10769 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
45542 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1174 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-183864 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1214206 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1127435 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1244940 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-133917 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3369079 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5498519 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7499839 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
355 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-999 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-110539 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
80696 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-134272 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-3368080 usd
us-gaap Profit Loss
ProfitLoss
-5387980 usd
us-gaap Profit Loss
ProfitLoss
-7580535 usd
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
52289 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-50564 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-255798 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-175813 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-186561 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3317516 usd
us-gaap Net Income Loss
NetIncomeLoss
-5132182 usd
us-gaap Net Income Loss
NetIncomeLoss
-7404722 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
25389 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15082 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-55106 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1995 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-161172 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3332598 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5187288 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7402727 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.08
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12405261 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4055345 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11164093 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11164093 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3555474 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3555474 shares
us-gaap Profit Loss
ProfitLoss
-5387980 usd
us-gaap Profit Loss
ProfitLoss
-7580535 usd
us-gaap Depreciation
Depreciation
21605 usd
us-gaap Depreciation
Depreciation
20949 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2957736 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1409969 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
38500 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1134029 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1422362 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
-146942 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-35719 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-191265 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-14177 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-27924 usd
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
4000 usd
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-2300 usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
467424 usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-189755 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
128189 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
648626 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
68516 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
246138 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-155697 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-112946 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1315534 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3756385 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21201 usd
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
493158 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-514359 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1050000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
394071 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2429028 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
737500 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
282095 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1352512 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
179125 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
164772 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
1000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1399313 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3831540 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-30686 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
168413 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
53093 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-270791 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
716780 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1391728 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
769873 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1120937 usd
us-gaap Interest Paid Net
InterestPaidNet
59519 usd
us-gaap Interest Paid Net
InterestPaidNet
27525 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
25863 usd
abvc Issuance Of Common Stock For Conversion Of Debt
IssuanceOfCommonStockForConversionOfDebt
845715 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3236139 usd
us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
140749 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1729028 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
451480 usd
us-gaap Profit Loss
ProfitLoss
-4212455 usd
us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
17077 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1362018 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1050000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
592000 usd
CY2023Q3 abvc Stock Issued During Period Value Issuance Of Common Stock For Acquiring Of Property
StockIssuedDuringPeriodValueIssuanceOfCommonStockForAcquiringOfProperty
7400000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1814800 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
700000 usd
CY2023Q3 abvc Stock Issued During Period Value Stock Exercise Of Prefunded Warrant
StockIssuedDuringPeriodValueStockExerciseOfPrefundedWarrant
-699800 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
225740 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-3368080 usd
CY2023Q3 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
-15082 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9061596 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8130972 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
811174 usd
us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
383500 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
394071 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2574236 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
737500 usd
abvc Stock Subscription Received
StockSubscriptionReceived
131040 usd
us-gaap Profit Loss
ProfitLoss
-5253708 usd
us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
-80495 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7828290 usd
CY2024Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
34540 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
191642 usd
CY2024Q3 abvc Stock Subscription Received
StockSubscriptionReceived
33732 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-134272 usd
CY2024Q3 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
25390 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7979322 usd
us-gaap Profit Loss
ProfitLoss
-5387980 usd
abvc Working Capital Deficit
WorkingCapitalDeficit
4167315 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1315534 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Reclassifications: </span></p>Certain amounts on the prior year’s condensed consolidated balance sheets, condensed consolidated statements of operations and condensed cash flows were reclassified to conform to the current-year presentation, with no effect on ending stockholders’ equity
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 25, 2023, the Company filed a Certificate of Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its common stock. The Company’s stockholders previously approved the Reverse Stock Split at the Company’s Special Shareholder Meeting held on July 7, 2023. The Reverse Stock Split was effected to reduce the number of issued and outstanding shares and to increase the per share trading value of the Company’s common stock, although that outcome is not guaranteed. In turn, the Company believes that the Reverse Stock Split will enable the Company to restore compliance with certain continued listing standards of the NASDAQ Capital Market. All shares and related financial information in this Form 10-Q reflect this 1-for-10 reverse stock split, unless otherwise specified.</p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
137344 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60155 usd
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
632529 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
656625 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of the limit of $94,500 (NTD 3 million) covered by Taiwan Central Deposit Insurance Corporation, and the limit of $250,000 covered by the U.S. Federal Deposit Insurance Corporation’s insurance limits. However, the Company does not anticipate any losses on excess deposits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company performs ongoing credit evaluations of our customers and requires no collateral. Credit losses and allowance for unbilled receivables are provided based on a review of the collectability of accounts receivable. The Company determines the amount of allowance for doubtful accounts by examining its historical collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit losses may differ from our estimates.</p>
CY2023Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.8119 pure
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
616457 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
616505 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 pure
CY2024Q3 us-gaap Payments For Rent
PaymentsForRent
191642 usd
us-gaap Payments For Rent
PaymentsForRent
191642 usd
abvc Milestone Payments Royalty Percentage
MilestonePaymentsRoyaltyPercentage
0.12 pure
CY2015 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
50000000 twd
CY2015Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
1640000 usd
CY2018Q4 abvc Equity Method Long Term Investment
EquityMethodLongTermInvestment
1530000 shares
CY2022Q2 abvc Service Agreement Eligibility Amount
ServiceAgreementEligibilityAmount
3000000 usd
CY2022Q2 abvc Milestone Regulatory Payment Amount Period
MilestoneRegulatoryPaymentAmountPeriod
P3Y
CY2024Q3 us-gaap Loans Payable
LoansPayable
1000000 usd
abvc Working Capital Convertible Loan Percentage
WorkingCapitalConvertibleLoanPercentage
0.05 pure
CY2024Q3 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
1
CY2024Q1 us-gaap Taxes And Licenses
TaxesAndLicenses
33500000 usd
CY2024Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
6
CY2024Q1 abvc Milestone Regulatory Payment Amount
MilestoneRegulatoryPaymentAmount
3500000 usd
CY2024Q1 abvc Royalties Percentage
RoyaltiesPercentage
0.05 pure
CY2024Q2 abvc Milestone Regulatory Payment Amount
MilestoneRegulatoryPaymentAmount
3500000 usd
CY2024Q2 abvc Licensing Agreement
LicensingAgreement
100000 usd
abvc Pursuant To The Amendment
PursuantToTheAmendment
3 usd
CY2024Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
296000 usd
CY2024Q3 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
200000 usd
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
200000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11276230 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11304319 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3344752 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3335041 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7931478 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7969278 usd
CY2024Q3 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
37000000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
7013 usd
CY2023Q3 us-gaap Depreciation
Depreciation
7459 usd
us-gaap Depreciation
Depreciation
21605 usd
us-gaap Depreciation
Depreciation
20949 usd
CY2024Q3 us-gaap Debt Securities Noncurrent
DebtSecuritiesNoncurrent
816160 usd
CY2023Q4 us-gaap Debt Securities Noncurrent
DebtSecuritiesNoncurrent
847252 usd
CY2024Q3 us-gaap Long Term Investments
LongTermInvestments
2333904 usd
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
2527740 usd
CY2022 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
2688578 usd
CY2022 us-gaap Prepayment Fees On Advances Net
PrepaymentFeesOnAdvancesNet
1895556 usd
CY2022 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
994450 shares
abvc Percentage Common Stocks Shares
PercentageCommonStocksShares
0.51 pure
CY2024Q3 us-gaap Real Estate Investments Joint Ventures
RealEstateInvestmentsJointVentures
150000 usd
CY2024Q3 us-gaap Equity Method Investments
EquityMethodInvestments
146942 usd
CY2024Q3 abvc Outstanding Principal Amount
OutstandingPrincipalAmount
308651 usd
abvc Percentage Of Cash Permium
PercentageOfCashPermium
0.05 pure
CY2023Q3 abvc Percentage Of Outstanding Principal Amount
PercentageOfOutstandingPrincipalAmount
1.15 pure
CY2024Q1 us-gaap General Partners Capital Account
GeneralPartnersCapitalAccount
12500000 usd
us-gaap Debt Instrument Issued Principal
DebtInstrumentIssuedPrincipal
3167292 usd
CY2023Q3 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
3.5
CY2024Q2 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
0.75
CY2023Q4 us-gaap Receivable With Imputed Interest Face Amount
ReceivableWithImputedInterestFaceAmount
1200000 usd
CY2023Q4 us-gaap Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed
DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
1.20 pure
CY2023Q4 abvc Purchase Warrant Term
PurchaseWarrantTerm
P5Y
CY2024Q1 us-gaap Receivable With Imputed Interest Face Amount
ReceivableWithImputedInterestFaceAmount
1000000 usd
CY2024Q1 abvc Purchase Price Amount
PurchasePriceAmount
833333 usd
CY2024Q1 us-gaap Common Stock Convertible Conversion Price Increase
CommonStockConvertibleConversionPriceIncrease
3.5
CY2024Q1 abvc Percentage Of Average Amount
PercentageOfAverageAmount
0.90 pure
CY2024Q1 us-gaap Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed
DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
1.20 pure
CY2024Q1 abvc Purchase Warrant Term
PurchaseWarrantTerm
P5Y
CY2024Q1 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
1000000 usd
CY2024Q1 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
2
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
394071 usd
CY2024Q2 us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
1000000 shares
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
847763 usd
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1441719 usd
abvc Convertible Debentures Cost
ConvertibleDebenturesCost
2160000 usd
CY2023 abvc Convertible Debentures Cost
ConvertibleDebenturesCost
2372851 usd
CY2024Q3 us-gaap Interest Expense Other
InterestExpenseOther
209022 usd
CY2023Q3 us-gaap Interest Expense Other
InterestExpenseOther
1198290 usd
us-gaap Interest Expense Other
InterestExpenseOther
1082936 usd
CY2024Q3 abvc Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
1799583 usd
CY2023Q4 abvc Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
1799583 usd
CY2024Q3 abvc Accrued Director And Officer Compensation
AccruedDirectorAndOfficerCompensation
1027080 usd
CY2023Q4 abvc Accrued Director And Officer Compensation
AccruedDirectorAndOfficerCompensation
988959 usd
CY2024Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
263972 usd
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
274028 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
89902 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
41426 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
452390 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
592484 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3632927 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3696380 usd
CY2024Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
866250 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
899250 usd
CY2024Q3 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.025 pure
CY2024Q3 us-gaap Interest Expense Short Term Borrowings
InterestExpenseShortTermBorrowings
3747 usd
CY2023Q3 us-gaap Interest Expense Short Term Borrowings
InterestExpenseShortTermBorrowings
3752 usd
us-gaap Interest Expense Short Term Borrowings
InterestExpenseShortTermBorrowings
11668 usd
us-gaap Interest Expense Short Term Borrowings
InterestExpenseShortTermBorrowings
11681 usd
abvc Schedule Of Pursuant Licensing Agreement Related Amendment Table Text B Lock
ScheduleOfPursuantLicensingAgreementRelatedAmendmentTableTextBLock
During the three and nine months ended September 30, 2024, the Company received $180,000 and $296,000, respectively, pursuant to the licensing agreement and related amendment with FEYE, and recognized $180,000 and $296,000 revenue correspondingly. In addition, the Company received $200,000 during the three and nine months ended September pursuant to the licensing agreement with OncoX, and recognized revenue correspondingly. Please refer to Note 4, Collaborative Agreements for details.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nine Months Ended</td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">September 30,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024 </b> </span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">   <b>(Unaudited)</b></span></td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">OncoX</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; width: 52%">FEYE</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">180,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">          -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">296,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">         -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><b style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Total</b></td><td style="padding-bottom: 4pt"><b> </b></td> <td style="border-bottom: Black 4pt double; text-align: left"><b>$</b></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">3<b>80,000</b></div></td><td style="padding-bottom: 2.5pt; text-align: left"><b> </b></td><td style="padding-bottom: 4pt"><b> </b></td> <td style="border-bottom: Black 4pt double; text-align: left"><b>$</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b style="-sec-ix-hidden: hidden-fact-196">-</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b> </b></td><td style="font-weight: bold; padding-bottom: 4pt"><b> </b></td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><b>$</b></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">4<b>96,000</b></div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><b> </b></td><td style="padding-bottom: 4pt"><b> </b></td> <td style="border-bottom: Black 4pt double; text-align: left"><b>$</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b style="-sec-ix-hidden: hidden-fact-198">-</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b> </b></td></tr> </table>
CY2024Q3 abvc Licensing Agreement
LicensingAgreement
180000 usd
CY2023Q3 abvc Licensing Agreement
LicensingAgreement
296000 usd
CY2024Q3 us-gaap Deferred Revenue
DeferredRevenue
180000 usd
CY2023Q3 us-gaap Deferred Revenue
DeferredRevenue
296000 usd
CY2022Q2 us-gaap Accounts Payable Interest Bearing Interest Rate
AccountsPayableInterestBearingInterestRate
0.05 pure
CY2022Q2 abvc Working Capital Percentage
WorkingCapitalPercentage
0.064 pure
abvc Description Of Conversion Price
DescriptionOfConversionPrice
The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.
CY2023Q4 us-gaap Principal Amount Outstanding On Loans Securitized
PrincipalAmountOutstandingOnLoansSecuritized
500000 usd
CY2023Q4 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
38819 usd
CY2024Q3 us-gaap Principal Amount Outstanding On Loans Securitized
PrincipalAmountOutstandingOnLoansSecuritized
606323 usd
CY2024Q3 us-gaap Principal Amount Outstanding On Loans Securitized
PrincipalAmountOutstandingOnLoansSecuritized
6302360 twd
us-gaap Repayments Of Debt
RepaymentsOfDebt
100076 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
3230000 twd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
839983 usd
CY2024Q3 us-gaap Accounts Payable Interest Bearing Interest Rate
AccountsPayableInterestBearingInterestRate
0.12 pure
CY2024Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
648716 usd
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
713223 usd
CY2024Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
5625854 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
5568391 usd
CY2024Q3 abvc Operating Lease Liabilities
OperatingLeaseLiabilities
213482 usd
CY2023Q4 abvc Operating Lease Liabilities
OperatingLeaseLiabilities
213482 usd
CY2024Q3 abvc Deferred Tax Assets Operating Lease Assets
DeferredTaxAssetsOperatingLeaseAssets
-213482 usd
CY2023Q4 abvc Deferred Tax Assets Operating Lease Assets
DeferredTaxAssetsOperatingLeaseAssets
-213482 usd
CY2024Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6274570 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6281614 usd
CY2024Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6274570 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6281614 usd
CY2023Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
300000 shares
CY2023Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.5
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2
CY2024Q3 abvc Volume Weighted Average Price
VolumeWeightedAveragePrice
64147 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46072 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1610700 shares
CY2024Q1 abvc Consulting Fee
ConsultingFee
383500 usd
CY2024Q1 us-gaap Land
Land
7670000 usd
CY2024Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
127270 shares
CY2023Q1 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
10.5
CY2024Q1 us-gaap Investment Sold Not Yet Purchased Balance Shares
InvestmentSoldNotYetPurchasedBalanceShares
751795 shares
CY2024Q1 us-gaap Investment Sold Not Yet Purchased Balance Principal Amount
InvestmentSoldNotYetPurchasedBalancePrincipalAmount
681000 usd
CY2024Q2 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
153508 shares
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
130175 usd
CY2024Q2 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
0.75
CY2023Q4 us-gaap Credit Derivative Term1
CreditDerivativeTerm1
P5Y
CY2023Q4 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
2
CY2023Q4 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
480795 usd
CY2024Q1 us-gaap Credit Derivative Term1
CreditDerivativeTerm1
P5Y
CY2024Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1000000 shares
CY2024Q2 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.75
CY2024Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1000000 shares
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
925210 usd
CY2024Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1000000 shares
CY2024Q3 us-gaap Proceeds From Repayment Of Loans To Purchase Common Stock
ProceedsFromRepaymentOfLoansToPurchaseCommonStock
200000 usd
CY2024Q3 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
88403 usd
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
200000 shares
CY2024Q3 us-gaap Proceeds From Repayment Of Loans To Purchase Common Stock
ProceedsFromRepaymentOfLoansToPurchaseCommonStock
200000 usd
CY2024Q3 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
90722 usd
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
200000 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
54518 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P10Y
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
258710 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.9
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
258710 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.9
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M26D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
258710 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
27.9
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y11M26D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
258710 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
27.9
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y11M26D
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0279 pure
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8386 pure
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-186561 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3317516 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12405261 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4055345 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12405261 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4055345 shares
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5132182 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7404722 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11164093 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3555474 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11164093 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3555474 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.08
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
507659 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
809283 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
365458 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
401826 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
142201 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
407457 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
134795 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
96875 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
397262 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
288751 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M9D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M23D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0046 pure
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.015 pure
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
101130 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
350088 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
56916 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
508933 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1274 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
507659 usd
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
usd
CY2023Q4 abvc Stock Subscription Received In Advance
StockSubscriptionReceivedInAdvance
usd
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2023Q3 abvc Operating Sublease Income
OperatingSubleaseIncome
usd
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
abvc Issuance Of Common Stock For Conversion Of Debt
IssuanceOfCommonStockForConversionOfDebt
usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
usd
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
usd
CY2024Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
abvc Sharebased Compensation Arrangement By Sharebased Payment Award Options Grant Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm
abvc Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
abvc Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeited Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
abvc Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedIntrinsicValue
usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
usd
CY2024Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001173313

Files In Submission

Name View Source Status
0001213900-24-097840-index-headers.html Edgar Link pending
0001213900-24-097840-index.html Edgar Link pending
0001213900-24-097840.txt Edgar Link pending
0001213900-24-097840-xbrl.zip Edgar Link pending
abvc-20240930.xsd Edgar Link pending
ea0216049-10q_abvcbio.htm Edgar Link pending
ea021604901ex31-1_abvcbio.htm Edgar Link pending
ea021604901ex31-2_abvcbio.htm Edgar Link pending
ea021604901ex32-1_abvcbio.htm Edgar Link pending
ea021604901ex32-2_abvcbio.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
abvc-20240930_def.xml Edgar Link unprocessable
abvc-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ea0216049-10q_abvcbio_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
abvc-20240930_cal.xml Edgar Link unprocessable
abvc-20240930_lab.xml Edgar Link unprocessable